Eli Lilly

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo- and Active-Controlled, Treat-Through Study to Evaluate the Efficacy and Safety of Mirikizumab in Patients with Moderately to Severely Active Crohn's Disease"

• Mirikizumab (LY3074828) is a humanized immunoglobulin G4 (IgG4) monoclonal antibody that binds to the p19 subunit of interleukin-23 (IL-23), a cytokine that has been implicated in mucosal inflammation.
• Patients must have an inadequate response to, loss of response to, or are intolerant to corticosteroid or immunomodulator therapy for CD and those who have an inadequate response to, loss of response to, or are intolerant to biologic therapy for CD
• Participants will be randomized in a 6:3:2 ratio to receive, respectively:

Mirikizumab 900 mg intravenously (IV) every 4 weeks (Q4W) for 3 doses, then 300 mg subcutaneously (SC) Q4W Ustekinumab ~6 mg/kg IV for one dose, then 90 mg SC every 8 weeks or Placebo

If you are interested in participating in clinical studies, please send an email to wagiresearch@washgi.com.